UBS Group AG (UBS) Reaches $19.59 52-Week High; Cytrx (CYTR)’s Sentiment Is 0.73

January 14, 2018 - By reb123z

CytRx Corporation operates as a biopharmaceutical research and development firm specializing in oncology. The company has market cap of $52.24 million. The companyÂ’s product candidate is the aldoxorubicin, which is in Phase III clinical trial as a therapy for patients with soft tissue sarcomas whose tumors have progressed following treatment with chemotherapy; in Phase IIb clinical trial in small cell lung cancer; in Phase II clinical trial in HIV-related Kaposi's sarcoma; in Phase II clinical trial in patients with late-stage glioblastoma (brain cancer); in Phase Ib trial in combination with ifosfamide in patients with STS; and in Phase Ib trial in combination with gemcitabine in subjects with metastatic solid tumors. It currently has negative earnings. It also has completed Phase IIb and Phase Ib/II clinical trials with aldoxorubicin as a first-line therapy for STS; a Phase Ib clinical trial of aldoxorubicin in combination with doxorubicin in patients with advanced solid tumors; and a Phase Ib pharmacokinetics clinical trial in patients with metastatic solid tumors.

The stock of UBS Group AG (NYSE:UBS) hit a new 52-week high and has $20.77 target or 6.00% above today’s $19.59 share price. The 5 months bullish chart indicates low risk for the $72.58 billion company. The 1-year high was reported on Jan, 14 by Barchart.com. If the $20.77 price target is reached, the company will be worth $4.35 billion more. The stock increased 1.50% or $0.29 during the last trading session, reaching $19.59. About 3.40M shares traded or 83.54% up from the average. UBS Group AG (NYSE:UBS) has risen 14.86% since January 14, 2017 and is uptrending. It has underperformed by 1.84% the S&P500.

Pekin Singer Strauss Asset Management Il holds 0.01% of its portfolio in CytRx Corporation for 67,555 shares. Bank Of America Corp De owns 2,144 shares or 0% of their US portfolio. Moreover, Bank Of Montreal Can has 0% invested in the company for 490 shares. The New York-based Bank Of New York Mellon Corp has invested 0% in the stock. Barclays Plc, a United Kingdom-based fund reported 9 shares.

The stock increased 1.61% or $0.03 during the last trading session, reaching $1.89. About 142,621 shares traded. CytRx Corporation (CYTR) has declined 78.08% since January 14, 2017 and is downtrending. It has underperformed by 94.78% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts